| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $202,154 | 6 | 100 |
Sells | $0 | 0 | 0 |
| Voss Capital, LP | 10 percent owner | 1 | $127,593 | 0 | $0 | $127,593 |
| VON RICKENBACH JOSEF H | director | 4 | $49,561 | 0 | $0 | $49,561 |
| WINDSOR JAMES BRIAN | See Remarks | 1 | $25,000 | 0 | $0 | $25,000 |
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, …
Over the last 12 months, insiders at Rein Therapeutics Inc. have bought $202,154 and sold $0 worth of Rein Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Rein Therapeutics Inc. have bought $312,810 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Voss Capital, LP (10 percent owner) — $127,593. VON RICKENBACH JOSEF H (director) — $49,561. WINDSOR JAMES BRIAN (See Remarks) — $25,000.
The last purchase of 4,500 shares for transaction amount of $4,819 was made by VON RICKENBACH JOSEF H (director) on 2026‑05‑27.
| 2026-05-27 | VON RICKENBACH JOSEF H | director | 4,500 0.0163% | $1.07 | $4,819 | -24.53% | ||
| 2026-05-26 | VON RICKENBACH JOSEF H | director | 23,190 0.0826% | $1.06 | $24,470 | -25.23% | ||
| 2026-05-22 | VON RICKENBACH JOSEF H | director | 15,950 0.058% | $1.05 | $16,708 | -22.33% | ||
| 2026-05-21 | VON RICKENBACH JOSEF H | director | 3,420 0.0123% | $1.04 | $3,564 | -23.07% | ||
| 2026-04-30 | WINDSOR JAMES BRIAN | See Remarks | 25,000 0.0699% | $1.00 | $25,000 | -39.85% | ||
| 2025-11-14 | Voss Capital, LP | 10 percent owner | 104,183 0.3915% | $1.22 | $127,593 | -12.80% | ||
| 2025-10-28 | Voss Capital, LP | 10 percent owner | 178,392 0.7608% | $1.39 | $247,965 | -14.39% | ||
| 2025-10-27 | Voss Capital, LP | 10 percent owner | 97,482 0.4097% | $1.37 | $133,544 | -15.56% | ||
| 2025-10-24 | Voss Capital, LP | 10 percent owner | 30,176 0.1287% | $1.39 | $41,957 | -20.83% |
| Voss Capital, LP | 10 percent owner | 926441 1.0739% | $618,399.37 | 4 | 0 | <0.0001% |
| VON RICKENBACH JOSEF H | director | 62514 0.0725% | $41,728.10 | 4 | 0 | |
| WINDSOR JAMES BRIAN | See Remarks | 27046 0.0314% | $18,053.21 | 1 | 0 |
| Increased Positions | 26 | +70.27% | 2M | +27.34% |
| Decreased Positions | 10 | -27.03% | 219,349 | -2.59% |
| New Positions | 13 | New | 457,912 | New |
| Sold Out Positions | 5 | Sold Out | 81,771 | Sold Out |
| Total Postitions | 53 | +43.24% | 11M | +24.75% |